Jazz Pharmaceuticals plc (JAZZ)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$1,844.3M
Cash & Equivalents
$408.2M
Quarterly Burn Rate
$15,316M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (4 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
FLUVOXAMINE MALEATE
LUVOX |
APPROVED | Acute Lung Injury, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL), Acute Lymphocytic Leukemia, Acute Lymphoid Leukemia, Acute Myelogenous Leukemia, Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukaemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Myeloid Leukemia, Adult, Acute Respiratory Distress Syndrome, Acute-graft-versus-host Disease, Adenovirus, Adenovirus Disease, Adenovirus Infection, Adenovirus Infections, Human, Advanced Cancer, Advanced Colorectal Cancer, Advanced Glioblastoma, Advanced Leiomyosarcoma, Advanced Non-Small Cell Lung Cancer, Advanced Pheochromocytoma and Paraganglioma, Advanced Soft Tissue Sarcoma, Advanced Solid Tumor, Advanced Triple-negative Breast |
|
LURBINECTEDIN
ZEPZELCA |
APPROVED | — |
|
CALCIUM OXYBATE, MAGNESIUM OXYBATE, POTASSIUM OXYBATE, SODIUM OXYBATE
XYWAV |
APPROVED | — |
|
CLOZAPINE
FAZACLO ODT |
NDA | — |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-25 | Pdufa | — |